This Article Full Text Full Text (PDF) All Versions of this Article: 40/3/329    most recent 01.HYP.0000028979.98877.0Cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shiuchi, T. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Shiuchi, T. Articles by Horiuchi, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 2-DEOXY-D-GLUCOSE NITRIC OXIDE Medline Plus Health Information Diabetes Related Collections ACE/Angiotension receptors

(Hypertension. 2002;40:329.)
© 2002 American Heart Association, Inc.

Scientific Contributions

ACE Inhibitor Improves Insulin Resistance in Diabetic Mouse Via Bradykinin and NO

Tetsuya Shiuchi; Tai-Xing Cui; Lan Wu; Hironori Nakagami; Yuko Takeda-Matsubara; Masaru Iwai; Masatsugu Horiuchi

From the Department of Medical Biochemistry, Ehime University School of Medicine, Ehime, Japan.

Correspondence to Dr Masatsugu Horiuchi, Department of Medical Biochemistry, Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime 791–0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

Improvement of insulin resistance by ACE inhibitors has been suggested; however, this mechanism has not been proved. We postulated that activation of the bradykinin-nitric oxide (NO) system by an ACE inhibitor enhances glucose uptake in peripheral tissues by means of an increase in translocation of glucose transporter 4 (GLUT4), resulting in improvement of insulin resistance. Administration of an ACE inhibitor, temocapril, significantly decreased plasma glucose and insulin concentrations in type 2 diabetic mouse KK-Ay. Mice treated with temocapril showed a smaller plasma glucose increase after glucose load. We demonstrated that temocapril treatment significantly enhanced 2-[³H]-deoxy-D-glucose (2-DG) uptake in skeletal muscle but not in white adipose tissue. Administration of a bradykinin B2 receptor antagonist, Hoe140, or an NO synthase inhibitor, L-NAME, attenuated the enhanced glucose uptake by temocapril. Moreover, we observed that translocation of GLUT4 to the plasma membrane was significantly enhanced by temocapril treatment without influencing insulin receptor substrate-1 phosphorylation. In L6 skeletal muscle cells, 2-DG uptake was increased by temocaprilat, and Hoe140 inhibited this effect of temocaprilat but not that of insulin. These results suggest that temocapril would improve insulin resistance and glucose intolerance through increasing glucose uptake, especially in skeletal muscle at least in part through enhancement of the bradykinin-NO system and consequently GLUT4 translocation.

Key Words: angiotensin-converting enzyme • bradykinin • glucose • insulin resistance • nitric oxide

This article has been cited by other articles:

				K. D. Hill, A. W. Eckhauser, A. Marney, and N. J. Brown Phosphodiesterase 5 Inhibition Improves {beta}-Cell Function in Metabolic Syndrome Diabetes Care, May 1, 2009; 32(5): 857 - 859. [Abstract] [Full Text] [PDF]

				I. Tabbi-Anneni, J. Buchanan, R. C. Cooksey, and E. D. Abel Captopril Normalizes Insulin Signaling and Insulin-Regulated Substrate Metabolism in Obese (ob/ob) Mouse Hearts Endocrinology, August 1, 2008; 149(8): 4043 - 4050. [Abstract] [Full Text] [PDF]

				M. Buleon, J. Allard, A. Jaafar, F. Praddaude, Z. Dickson, M.-T. Ranera, C. Pecher, J.-P. Girolami, and I. Tack Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1249 - F1256. [Abstract] [Full Text] [PDF]

				D. K McGuire, J. R Winterfield, J. A Rytlewski, and E. Ferrannini Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus Diabetes and Vascular Disease Research, March 1, 2008; 5(1): 59 - 66. [Abstract] [PDF]

				M.-K. Sim, X.-G. Xu, Y.-C. Wong, S.-Z. Sim, and K.-O. Lee Des-Aspartate-Angiotensin I Exerts Hypoglycemic Action via Glucose Transporter-4 Translocation in Type 2 Diabetic KKAy Mice and GK Rats Endocrinology, December 1, 2007; 148(12): 5925 - 5932. [Abstract] [Full Text] [PDF]

				M. Iwai, H.-S. Li, R. Chen, T. Shiuchi, L. Wu, L.-J. Min, J.-M. Li, M. Tsuda, J. Suzuki, Y. Tomono, et al. Calcium Channel Blocker Azelnidipine Reduces Glucose Intolerance in Diabetic Mice via Different Mechanism Than Angiotensin Receptor Blocker Olmesartan J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1081 - 1087. [Abstract] [Full Text] [PDF]

				K. M. Beard, H. Lu, K. Ho, and I. G. Fantus Bradykinin Augments Insulin-Stimulated Glucose Transport in Rat Adipocytes via Endothelial Nitric Oxide Synthase-Mediated Inhibition of Jun NH2-Terminal Kinase. Diabetes, October 1, 2006; 55(10): 2678 - 2687. [Abstract] [Full Text] [PDF]

				A. Mate, A. Barfull, A. M. Hermosa, L. Gomez-Amores, C. M. Vazquez, and J. M. Planas Regulation of sodium-glucose cotransporter SGLT1 in the intestine of hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R760 - R767. [Abstract] [Full Text] [PDF]

				V. Wong, L. Szeto, K. Uffelman, I G. Fantus, and G. F Lewis Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway. J. Endocrinol., August 1, 2006; 190(2): 441 - 450. [Abstract] [Full Text] [PDF]

				C. J. Saunders, S. L. Xenophontos, M. A. Cariolou, L. C. Anastassiades, T. D. Noakes, and M. Collins The bradykinin {beta}2 receptor (BDKRB2) and endothelial nitric oxide synthase 3 (NOS3) genes and endurance performance during Ironman Triathlons Hum. Mol. Genet., March 15, 2006; 15(6): 979 - 987. [Abstract] [Full Text] [PDF]

				C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1437 - 1446. [Abstract] [Full Text] [PDF]

				E. Aihara, M. Hayashi, Y. Sasaki, A. Kobata, and K. Takeuchi Mechanisms Underlying Capsaicin-Stimulated Secretion in the Stomach: Comparison with Mucosal Acidification J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 423 - 432. [Abstract] [Full Text] [PDF]

				T. Fujiki, H. Shimokawa, K. Morikawa, H. Kubota, M. Hatanaka, M.A. H. Talukder, T. Matoba, A. Takeshita, and K. Sunagawa Endothelium-Derived Hydrogen Peroxide Accounts for the Enhancing Effect of an Angiotensin-Converting Enzyme Inhibitor on Endothelium-Derived Hyperpolarizing Factor-Mediated Responses in Mice Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 766 - 771. [Abstract] [Full Text] [PDF]

				S. R. Kashyap, L. J. Roman, J. Lamont, B. S. S. Masters, M. Bajaj, S. Suraamornkul, R. Belfort, R. Berria, D. L. Kellogg Jr., Y. Liu, et al. Insulin Resistance Is Associated with Impaired Nitric Oxide Synthase Activity in Skeletal Muscle of Type 2 Diabetic Subjects J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1100 - 1105. [Abstract] [Full Text] [PDF]

				H. Katzov, A. M. Bennet, P. Kehoe, B. Wiman, M. Gatz, K. Blennow, B. Lenhard, N. L. Pedersen, U. de Faire, and J. A. Prince A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity Hum. Mol. Genet., November 1, 2004; 13(21): 2647 - 2657. [Abstract] [Full Text] [PDF]

				A. Prasad and A. A. Quyyumi Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome Circulation, September 14, 2004; 110(11): 1507 - 1512. [Full Text] [PDF]

				M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator-Activated Receptor-{gamma} Activity Circulation, May 4, 2004; 109(17): 2054 - 2057. [Abstract] [Full Text] [PDF]

				C. S. Carter, M. Cesari, W. T. Ambrosius, N. Hu, D. Diz, S. Oden, W. E. Sonntag, and M. Pahor Angiotensin-Converting Enzyme Inhibition, Body Composition, and Physical Performance in Aged Rats J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2004; 59(5): B416 - B423. [Abstract] [Full Text] [PDF]

				S. C. Benson, H. A. Pershadsingh, C. I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M. A. Avery, and T. W. Kurtz Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR{gamma}-Modulating Activity Hypertension, May 1, 2004; 43(5): 993 - 1002. [Abstract] [Full Text] [PDF]

				T. Shiuchi, M. Iwai, H.-S. Li, L. Wu, L.-J. Min, J.-M. Li, M. Okumura, T.-X. Cui, and M. Horiuchi Angiotensin II Type-1 Receptor Blocker Valsartan Enhances Insulin Sensitivity in Skeletal Muscles of Diabetic Mice Hypertension, May 1, 2004; 43(5): 1003 - 1010. [Abstract] [Full Text] [PDF]

				R. Chen, M. Iwai, L. Wu, J. Suzuki, L.-J. Min, T. Shiuchi, T. Sugaya, H.-W. Liu, T.-X. Cui, and M. Horiuchi Important Role of Nitric Oxide in the Effect of Angiotensin-Converting Enzyme Inhibitor Imidapril on Vascular Injury Hypertension, October 1, 2003; 42(4): 542 - 547. [Abstract] [Full Text] [PDF]

				R. A Defronzo Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance? The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S24 - S40. [Abstract] [PDF]